9 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 9 of 9 clinical reviews.
A clinical review of ipamorelin dosing considerations for Black and African ancestry patients, covering the pharmacogenomic and comorbidity evidence that exists and the ipamorelin-specific evidence that does not. Pending qualified medical review.
A analysis of ipamorelin pharmacogenomics, dosing considerations, and documented efficacy differences in East Asian patients, with primary-source citations throughout.
Evidence-based guide to ipamorelin acetate dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, GH-axis variation, and practical dose-adjustment strategies.
A detailed clinical review of how East Asian ancestry affects ipamorelin acetate safety, pharmacogenomics, and dosing thresholds, with primary-source citations and practical guidance for prescribers.
Evidence review of ipamorelin acetate efficacy differences in Black and African ancestry populations, covering pharmacogenomics, GH axis variability, GHSR polymorphisms, and race-stratified clinical data gaps.
A guide to ipamorelin acetate pharmacogenomics, dosing, and safety considerations specific to Hispanic and Latino patients, including CYP variant data, diabetes co-morbidity risk, and ethnicity-stratified evidence.
Evidence-based review of ipamorelin acetate safety, dosing, and pharmacogenomic considerations specific to Black and African ancestry populations, including GH-axis variability, G6PD status, and renal monitoring.
Evidence-based review of ipamorelin acetate efficacy in Hispanic and Latino populations, including pharmacogenomic factors, insulin resistance phenotypes, and clinical considerations for dosing optimization.
Evidence-based guide to ipamorelin acetate dosing considerations for South Asian patients, covering pharmacogenomics, metabolic phenotype differences, body composition factors, and clinical monitoring protocols.